Seattle-based Mozart Therapeutics closed on a $55 million Series A financing round, led by seed financier ARCH Venture Partners along with Sofinnova Partners. Additional investors were Eli Lilly and Company, MRL Ventures Fund, an early-stage fund run by Merck & Co., Leaps by Bayer, Altitude Life Science Ventures, and Alexandria Venture Investments.

Vertex Pharmaceuticals announced positive Day 90 data from the first patient in the company’s Phase I/II study of VX-880 in type 1 diabetes (T1D). The therapy is a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy.

A study published in Nature Communications reveals that patients who had been hospitalized with severe Covid-19 might not be totally safe after recovery, as they are more likely to harbor self-attacking antibodies than those who did not have the virus.

Boston-based Alexion Pharmaceuticals announced positive topline data from the company’s Phase III trial of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis.

Shares of Calliditas Therapeutics soared in trading after the company announced positive Phase III data from a study of Nefecon in IgA nephropatjhy (IgAN), an autoimmune renal disease.

Biotech company Kancera AB received clearance from the Swedish Medical Products Agency to initiate a clinical trial of KAND567, which blocks the Fractalkine receptor that plays a major role in triggering the body’s inflammatory process.

Alpine Immune Sciences shares exploded 211 percent in premarket trading at news of a global option and license deal with AbbVie.

U.K.-based Bit Bio, a spinout of Cambridge University and previously known as Elpis Biotechnology, secured $41.5 million in a Series A funding round that will be used to support the company’s goal to transition biology into engineering.

AstraZeneca’s cancer drug Calquence has shown initial signs of helping hospitalized COVID-19 patients get through the worst of the disease, as researchers scramble to repurpose existing treatments to help fight the deadly infection.

Argenx announced positive topline results from the company’s Phase III ADAPT clinical trial of efgartigimod for myasthenia gravis.